Shire Pharmaceuticals was acquired by Japan's Takeda Pharmaceuticals shareholders

shareholders backed the company's proposed acquisition of Shire for 46 billion pounds., Takeda announced an agreement to buy the company after its merger proposal was rejected four times by Hill., the European Commission, the U.S. Federal Trade Commission, the Japan Fair Trade Commission, China's National Market Regulatory Authority and Brazil's Economic and Defense Regulatory Commission, among other regulators, have approved the agreement.at a special general meeting of shareholders, at least 88 per cent voted in favour of the deal to merge the group, which will be headquartered in Japan."We are pleased that our shareholders have given us strong support for our acquisition of Shire," said Christopher Weber, Chief Executive Officer of Takeda.financial times said earlier this year that if completed, the deal would be one of the biggest in the industry and mark an important moment for Japanese companies to grow as global dealmakers. (This net special article)